ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 731.3 USD | +0.69% |
|
-2.59% | +25.46% |
| Apr. 22 | Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates | RE |
| Apr. 22 | Eli Lilly Acquires Injectables Manufacturing Facility in Wisconsin from Nexus Pharmaceuticals | MT |
Presenter SpeechTerence Flynn (Analysts)Great. Well, thanks, everybody, for joining us. I'm Te...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
731.3
USD
Average target price
813.3
USD
Spread / Average Target
+11.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.46% | 659B | |
| +26.63% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.21% | 215B | |
| +8.18% | 210B | |
| -6.05% | 200B | |
| -8.79% | 149B | |
| -5.59% | 146B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Transcript : Eli Lilly and Company Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 11
